Omnipaque (iohexol) Injection, 180mgI/mL, 20 mL Single-Dose Vial, packaged in 10 x 20 mL Vials per carton, Rx only, Distributed by GE Healthcare Inc., Marlborough, MA 01752 U.S.A.; Manufactured by GE Healthcare AS, Oslo, Norway; NDC 0407-1411-20.
Published December 26, 2018 · Recall initiated: October 29, 2018
Summary
FDA records drug Class II recall D-0319-2019, published December 26, 2018 and initiated October 29, 2018. Recalling firm: GE Healthcare Inc. Life Sciences; Status: Terminated; Reported quantity: 1092 cartons; Lot: Lot #: 14301544, Exp 21Sep21. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Defective Container: vial defect was identified that could potentially impact the container closure and result in a lack of sterility assurance and/or the potential for glass particles.
What to do
Voluntary: Firm initiated · Letter
Get an email if OMNIPAQUE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- OMNIPAQUE
- Manufacturer
- GE Healthcare Inc. Life Sciences
- Distributor
- TN
- Lot
- Lot #: 14301544, Exp 21Sep21
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAGE Healthcare Omnipaque (iohexol) Injection, 300 mg/mL (64.7%), Rx Only, Distributed by: GE Healthcare Inc.,April 15, 2026
- FDAGE Healthcare Omnipaque (iohexol) Injection, 350 mg/mL (64.7%), Rx Only, Distributed by: GE Healthcare Inc.,April 15, 2026
- FDAEstradiol Tablets, USP, 2 mg, 100-count bottle, Rx Only, Distributed by: Epic Pharma, LLC Laurelton, NY 11413,December 26, 2018
- FDAFentanyl Citrate 2 mcg per mL (200 mcg per 100 mL) and Ropivacaine HCl 0.2% in Sodium Chloride 0.9%,December 26, 2018
- FDAinfants* IBUPROFEN, Concentrated Ibuprofen Oral Suspension, USP (NSAID), 50 mg per 1.25 mL, Dye-Free BerryDecember 26, 2018
- FDABinding Site Human IgM Kit (for SPAPLUS), REF: NK012.S The device consists of reaction buffer, sheep anti-IgMDecember 19, 2018
Questions about this recall
Was Omnipaque (iohexol) Injection, 180mgI/mL, 20 mL Single-Dose Vial, packaged in 10 x 20 mL Vials per carton, Rx only, Distributed by GE Healthcare Inc., Marlborough, MA 01752 U.S.A.; Manufactured by GE Healthcare AS, Oslo, Norway; NDC 0407-1411-20. recalled?
Yes. FDA published recall D-0319-2019 on December 26, 2018. Reported hazard: Defective Container: vial defect was identified that could potentially impact the container closure and result in a lack of sterility assurance and/or the potential for glass particles.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: OMNIPAQUE.